Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here is the link:
http://qiaer.com/zaiyxm1.asp
And this link is one patient's story about IIA:
http://qiaer.com/kangags-1.asp?ShowId=27&ClassName=抗癌故事
Here is another link, he is talking about his farther joined IIB test. After two periods, all tumors are gone:
http://www.51qiji.com/bbs/dispbbs.asp?boardID=8&ID=5644&page=1
Your post is very helpful.
Even in conjunction with other drugs, a 100% either stable disease or partial recovery for lung cancer is impressive.
Do you have the exact link for those phase IIA and IIB results? I only saw three case studies on the site.
For the case studies, two were adenocarcinoma. From what I understand, adenocarcinoma is among the easiest to treat anyway. However the results of Rh-Apo2L for the tumor behind the eye were were remarkable.
Here is the link of Shanghai Qiaer wibsite(Aida's research subsidiary) http://qiaer.com/enindex01.asp
It provides some detail info about anti-cancer drug, Rh-Apo2L phase two testing in Chinese.
Here is the translation in English:
We started phase IIA at 22 hospitals and cancer research centers in China from March 2007.
Phase IIA:
Rh-Apo2L have shown better safety than phase I over 100 human patients using only Rh-Apo2L on 9 kind of cancers;
we evaluated 33 patients after two periods, it shows:
One PR for lymphoma cancer, reduced over 60%
one MR for lung cancer, rescued 32%
one MR for stomach cancer, reduced 39%
one MR for melanoma, reduced 35%
one MR soft tissue cancer, reduced 30%
two MR for kidney cancer, reduced over 40%
total effects over 60%
for lung, stomach and liver cancers, total effects over 70%
Over 50% patients are SD.
We believe it will have better effects on more periods.
Phase IIB:
Phase IIB is testing Rh-Apo2L in combination with other anti-cancer drugs on lung cancer, stomach cancer and pancreatic cancer
started from Aug. 2007.
after two periods testing on 23 lung cancer patients, all of them is SD and PR is over 50%.
I contacted one of testing doctor and he said phase III test will start in March or April.
I've never purchased any securities or derivatives that way. Generally and as far as I know, the only restriction is that a person has to be an accredited investor--a person making at least $200,000/year or with $1,000,000 in assets. I would guess the company could provide details on how to purchase the units. Other than that, I don't know that much about it.
For the units, they seem almost fairly valued at $2.20 per unit. If you don't get the units, you're probably not missing out on too much.
On a different subject, it would be nice to hear from the company whether they started phase III trials.
AIDA filed form 424B3 to sell 1.2M units by Aida and 1.3M stocks by Panasia Strategy Investment Co. Ltd.
I just want to know how to buy these units for indivadual investor ? Thanks,
You're in the same situation as I am. Waiting for more data.
It's certainly a new direction for a drug and it has significant potential. Other than that, in my opinion, Aida's current Etimicin business seems enough to make the stock worth the current price. I believe the stock is a good risk.
Yes, I do speak Chinese. I have friends in China and they find these hospitals phone number for me.
The whole results have not reported yet. I just collected a few info from two hospitals.
Someone said it is good and someone said it is so so.
They said there is no any other drugs on market, so this one looks like better than nothing!
I bought some a few months ago and want to wait Phase II report and Phase III testing approval.
If it is really good, I will buy more too.
That's great that you made those calls! Do you speak Chinese? Did they give any specific numbers or say where the results could be found?
I don't get the impression there will be legal issues. The impression I got was that there was a public research report released a few years ago and Genentech started developing the drug in the U.S. while Aida's subsidiary independently started developing it in China. I did look around to see what the legal landscape was like and it doesn't seem like there is too much litigation in that area. It looks like Benda Pharmaceuticals has a similar issue with Introgen regarding a different drug but as far as I know, Benda hasn't been sued either.
I would love to see the actual results of the phase II clinical trials for Aida. Their PR which simply stated, "high efficacy" doesn't cut it for me. If I knew the drug was really good in quantitative terms, I would probably buy more.
I made several phone calls to these clinical testing Chinese hospitals and the result looks good. Some hospital just did IIA and others did IIA, IIB; and going to do IIC.
It is safe and good work with radiation therapy for cancer. I hope they can get approval by SFDA at the end of this year.
They applied several patents in China and some of them got approval for this drug; Genentech and Amgen applied the patents in USA.
Do you see any potential legal issues about this drug ?
As I understand Aida can sell its product in China and Genentech/Amgen can sell their produce in US; if Aida wants to sell its drug in US, Aida has to pay the license fee to Genentech/Amgen; the same thing applied to Genentech/Amgen’s drug too.
I don't have a good opinion on that either way and I don't know whether it's an insider. It may be. Regardless, that is about 5% of the outstanding shares so it's not insignificant.
Any idea about one insider wants to sell 1.3M shares at 1.17 ?
Why he does not have any confidence with the company and the new drugs ?
For Genentech's phase I results on patients with tumors, the drug was well tolerated. Follow ups showed about half had stable disease and about 40% had cancer progression.
Here's a link...
http://meeting.ascopubs.org/cgi/content/abstract/24/18_suppl/3013
The terms of the 1.2M shares and warrants doesn't seem too bad. It could potentially increase the share count by 13% but the offering price doesn't seem too far away from where it should be.
Hi PaperProphet, Do you know anything about Genentech and Amgen Phase I result ? any good news for their Rh-Apo2L test ?
Thanks
SB-2/A, is it put some pressure on the stock ?
going to sell 1.3M shares and 1.2M units.
one unit
Units, consisting of one share of Common Stock, par value $0.001 (“Common Stock”), one Redeemable Class A Warrant (“Class A Warrants”) and one Redeemable Class B Warrant (“Class B Warrants”)(2)
1,200,000 $2.20 per Unit $2,640,000 $81.04 Common Stock includable in Units
1,200,000
Common Stock issuable upon exercise of Class A Warrants
1,200,000 $2.50 per share $3,000,000 $92.10
Common Stock issuable upon exercise of Class B Warrants
1,200,000 $3.00 per share $3,600,000 $110.52
TOTAL
$10,780,500 $330.35 *
News today. Aida receives an award and associated monies of $164,982.47 from the Science and Technology Department of Zhejiang Province for thier anti-cancer drug, Rh-Apo2L.
I suspect what shareholders really want to hear are the statistics and results of the phase II trials. I wasn't able to find the results of the phase I trials either. For phase II, the only thing they say is "strong efficacy" but they don't give any meaningful details. Saying "strong efficacy" is a subjective opinion. Most people would rather invest in facts and not in adjectives.
---"Phase 2 testing results thus far have shown strong efficacy in treating lung cancer (non-small cell), non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer."---
I've been slowly buying shares and got a few more today. It's hard to buy since it's thinly traded.
I think Aida will be at least a three-bagger at some point within the next year even if nothing happens with their new drugs. My opinion only, of course. If anyone else stumbling across this board is following this company, please leave your opinion of the company.
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
170
|
Created
|
12/26/07
|
Type
|
Free
|
Moderators |
This is the board for Aida Pharmaceuticals, a company based in Hangzhou, China. Aida's primary revenue-producing product is an antibiotic named Etimicin but Aida is currently developing other drugs as well. Earnings (late 2007) may be somewhat depressed as there is a new mandate in China which requires hospitals to purchase drugs only from pharmaceutical manufacturers and this has hurt results somewhat as distributors returned sales to Aida. Aida expects that this issue is resolved. Aida's earnings, similar to other Chinese pharmaceutical companies, appear to be highly seasonal with most of the revenues occuring during the fourth quarter.
Revenues/Earnings are as follows (some data is derived from other filings) ($):
Qtr: | Rev: | COGS: | Gr Pft | SG&A | Other | NI: | CompNI | Shs: | per sh. |
3Q05 | $6,249,343 | $1,543,179 | $4,706,164 | $3,210,978 | _ | $730,540 | $817,007 | 23,375,000 | $0.035 |
4Q05 | 8,445,457 | 4,163,018 | 4,282,439 | 4,903,129 | _ | -30,452 | -20,372 | 23,481,849 | -0.001 |
1Q06 | 5,331,827 | 2,983,114 | 2,348,713 | 2,327,879 | _ | 14,536 | 58,237 | 25,000,000 | 0.002 |
2Q06 | 7,284,888 | 3,579,700 | 3,705,188 | 2,803,043 | _ | 398,888 | 414,243 | 25,000,000 | 0.017 |
3Q06 | 7,023,891 | 3,103,516 | 3,920,375 | 2,481,226 | _ | 919,285 | 968,626 | 25,000,000 | 0.039 |
4Q06 | 10,002,497 | 4,414,710 | 5,587,787 | 3,688,802 | _ | 120,875 | 296,941 | 27,000,000 | 0.011 |
1Q07 | 5,296,176 | 2,972,516 | 2,323,660 | 2,164,150 | _ | -160,204 | 42,574 | 27,000,000 | 0.002 |
2Q07 | 6,419,476 | 3,605,286 | 2,814,190 | 1,965,568 | _ | -16,315 | 367,603 | 27,000,000 | 0.014 |
3Q07 | 7,373,770 | 3,557,685 | 3,816,085 | 2,379,034 | _ | 519,061 | 541,213 | 27,000,000 | 0.020 |
4Q07 | 10,114,364 | 4,375,195 | 5,739,169 | 2,454,876 | _ | 2,397,283 | 2,193,730 | 27,000,000 | 0.081 |
1Q08 | 7,652,017 | 3,700,057 | 3,951,960 | 2,984,642 | _ | -18,980 | 56,193 | 27,000,000 | 0.002 |
2Q08 | 10,899,924 | 4,731,941 | 6,167,983 | 4,211,180 | -8,077,264* | -6,771,364 | -6,960,862 | 27,000,000 | -0.26 |
3Q08 | 11,885,458 | 4,958,239 | 6,927,219 | 4,069,538 | _ | 2,289,681 | 2,361,682 | 27,000,000 | 0.08 |
* During the second quarter of 2008, a company called Nanwang Information Industry Group Co. defaulted on its loans. Aida was the guarantor of Nanwang's loan and had to repay around 50M RMB (about $7,000,000) to make good on Nanwang's default. This resulted in the extraordinary loss per share during the second quarter of 2008. In addition, $1,032,141 was paid out as a consulting fee for previous business development work.
Aida has also won several patent infringement suits against other Chinese companies which were counterfeiting Aida's products. This, combined with the Chinese government's mandate to only purchase pharmaceuticals directly from the manufacturers, could positively impact Aida's bottom line.
While the Etimicin sales seem promising, Aida Pharmaceuticals is really interesting because of the situation regarding their anti-cancer drug under development called Rh-Apo2L. This is being produced by subsidiary of Aida's called Shanghai Qiaer Bio-technology Co., Ltd which is 77.5% owned by Aida. The drug works by triggering apoptosis (programmed cell death) in cancer cells. Phase II testing has shown strong efficacy with fewer side effects than other anti-cancer drugs.
Despite the potential, the share price is possibly depressed since Rh-Apo2L is also being developed separately by Genentech and Amgen in the United States. The basis for Rh-Apo2L appears to be a public research paper published in the U.S.. In China, Qiaer (Aida) began work on the drug while in the U.S., Genentech and Amgen began work on the drug. Genentech and Amgen are obviously much bigger than Aida. Patent situations in China are fledgling and uncertain but this could certainly be an issue. Aida currently has patents on the drug in China while Genetech and Amgen undoubtedly have patents in the U.S.. If Genentech and Amgen feel they have claims over Aida's intellectual property, the dispute could hurt Aida.
The R&D landscape in China is that China can finish clinical trials much faster than the United States due to delays in the U.S. due to FDA approvals. This makes it seem probable that Aida will begin marketing the drug before Genentech and Amgen. Other issues are the lack of or reduced patent protection and enforcement. Chinese companies often manufacture U.S. drugs despite patent protection in the U.S.. Pfizer recently won a landmark suit in China against a Chinese company which was producing Viagra.
However, unlike the Pfizer case, theft of intellectual property doesn't seem to be the issue with Aida. Aida went through all the development of Rh-Apo2L themselves. While the Pfizer case was against a company which copied even the name "Viagra," Aida hasn't taken any intellectual property as far as is known. The coincidence of the name of the drug being co-developed, Rh-Apo2L (recombinant Apo2L), refers to the type of protein and not any trademarked name.
If all goes well with commercialization, the current share price is undoubtedly cheap. If commercialization doesn't go well, the company still has its profitable Etimicin sales as well as other drugs in the pipeline and this may limit the downside risk. Given the current profitable business and the large potential, Aida seems like a very attractive play.
Company's website: http://en.aidapharma.com
Press Releases (abbreviated from full press releases):
3/27/08 Aida Acquires High-Level Research Institute in China (Jiangsu Institute of Microbiology Co.) "The acquisition is expected to yield multiple new products for Aida, including several that are already in clinical trials by China's State Food and Drug Administration."
4/9/2008: Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development "...its recently-acquired research institute in the Jiangsu Province, the Jiangsu Institute of Microbiology Co., Ltd or "JSIM", is developing a new wide-spectrum antibiotic, Wetimicin, in the People's Republic of China. Wetimicin is from the newest generation of amino-glycoside family of antibiotics and is being tested for the treatment of various inflammations, such as respiratory infection, urinogenital infection, soft skin tissue infection as well as infections from trauma and operations, etc. JSIM's scientists believe that it might be safer and more reliable for children and elderly patients than current drug offerings in the marketplace."
4/18/08 Aida Announces New Anti-Cancer Drug Under Development "...it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer. Vasostatin-Apo2L, a pre-clinical product being developed by Aida's Shanghai Qiaer subsidiary, is a recombinant fusion protein that integrates the function of extracted fragments of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of Rh-Apo2L, which induces the apoptosis of cancer cells."
4/22/08 Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website http://en.aidapharma.com
4/24/08: Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition "...it has completed the acquisition of a controlling interest in Jiangsu Institute of Microbiology Co., Ltd. ("JSIM"), one of the leading microbiology research institutes in the People's Republic of China."
4/28/08 Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing "...the Company is compiling data for its Phase 2 testing results of Rh-Apo2L and expects to announce the findings within the next month. The Company previously announced that the target cancers for the drug have been determined and initial results are extremely positive."
12/03/08 Aida Pharmaceutials files 15-12G, certification of notices of termination of registration, with the SEC. This will mean that Aida's shares will move to the pink sheets.
Moderating policy: All positive and negative opinions alike will be allowed and even occasional digressions (within reason) will be allowed. 'Moderating' will be kept to a minimum. The philosophy behind this is that some conflict and differing opinions is normal, that readers can form their own opinions from what they read and that readers usually don't need to be protected from posts by a moderator. Adverse opinions or misinformation can be refuted by other posters. If you feel this policy is inadequate or if you feel you are vulnerable to what others may say, it may be advisable for you to avoid this board. In addition, this board is no substitute for due diligence.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |